Adherence to Antiseizure vs Other Medications Among US Medicare Beneficiaries With and Without Epilepsy.

Terman, Samuel Waller; Kerr, Wesley T; Aubert, Carole E; Hill, Chloe E; Marcum, Zachary A; Burke, James F (2022). Adherence to Antiseizure vs Other Medications Among US Medicare Beneficiaries With and Without Epilepsy. Neurology, 98(4), e427-e436. Lippincott Williams & Wilkins 10.1212/WNL.0000000000013119

Preview	Text Terman_Neurology_2021_AAM.pdf - Accepted Version Available under License Publisher holds Copyright. Download (3MB) | Preview
	Text Terman_Neurology_2022.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (533kB)

OBJECTIVE

To 1) compare adherence to antiseizure medications (ASMs) versus non-ASMs among individuals with epilepsy, 2) assess the degree to which variation in adherence is due to differences between individuals versus between medication classes among individuals with epilepsy, and 3) compare adherence in individuals with versus without epilepsy.

METHODS

This was a retrospective cohort study using Medicare. We included beneficiaries with epilepsy (≥1 ASM, plus International Classification of Diseases, Ninth Revision, Clinical Modification diagnostic codes), and a 20% random sample without epilepsy. Adherence for each medication class was measured by the proportion of days covered (PDC) in 2013-2015. We used Spearman correlation coefficients, Cohen's kappa statistics, and multilevel logistic regressions.

RESULTS

There were 83,819 beneficiaries with epilepsy. Spearman correlation coefficients between ASM PDCs and each of the 5 non-ASM PDCs ranged 0.44-0.50, Cohen's kappa ranged 0.33-0.38, and within-person differences between each ASM's PDC minus each non-ASM's PDC were all statistically significant (p<0.01) though median differences were all very close to 0. Fifty-four percent of variation in adherence across medications was due to differences between individuals. Adjusted predicted probabilities of adherence were: ASMs 74% (95% confidence interval [CI] 73%-74%), proton pump inhibitors 74% (95% CI 74%-74%), antihypertensives 77% (95% CI 77%-78%), selective serotonin reuptake inhibitors 77% (95% CI 77%-78%), statins 78% (95% CI 78%-79%), and levothyroxine 82% (95% CI 81%-82%). Adjusted predicted probabilities of adherence to non-ASMs were 80% (95% CI 80%-81%) for beneficiaries with epilepsy versus 77% (77%-77%) for beneficiaries without epilepsy.

CONCLUSION

Among individuals with epilepsy, ASM and non-ASM adherence were moderately correlated, half of variation in adherence was due to between-person rather than between-medication differences, adjusted adherence was slightly lower for ASMs than several non-ASMs, and epilepsy was associated with a quite small increase in adherence to non-ASMs. Nonadherence to ASMs may provide an important cue to the clinician to inquire about adherence to other potentially life-prolonging medications as well. Although efforts should focus on improving ASM adherence, patient-level rather than purely medication-specific behaviors are also critical to consider when developing interventions to optimize adherence.

Interest & Impact

Downloads

103 since deposited on 15 Dec 2021
57 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item